StreetInsider.com News Articles

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Tue, 16 Jun 2026 07:00:00 -0400

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
500,000-1 million people are estimated to be living with FSGS in the territories^[1]
Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
- US$10 million (~AU$14.1 million²) upfront payment
- Up to US$330 million (~AU$467 million²) in potential milestone payments
- Tiered royalties on net sales
Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Tue, 28 Apr 2026 07:00:00 -0400

Key Highlights:

An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion
To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint
As

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Tue, 28 Apr 2026 07:00:00 -0400

Key Highlights:

An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion
To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint
As

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Tue, 28 Apr 2026 07:00:00 -0400

Key Highlights:

An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion
To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint
As

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Tue, 28 Apr 2026 07:00:00 -0400

Key Highlights:

An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion
To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint
As

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Tue, 28 Apr 2026 07:00:00 -0400

Key Highlights:

An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion
To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint
As

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Tue, 28 Apr 2026 07:00:00 -0400

Key Highlights:

An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion
To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint
As

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Tue, 28 Apr 2026 07:00:00 -0400

Key Highlights:

An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion
To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint
As

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Tue, 28 Apr 2026 07:00:00 -0400

Key Highlights:

An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion
To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint
As

Dimerix completes recruitment for DMX-200 kidney disease trial

Mon, 15 Dec 2025 02:00:20 -0400

Dimerix Limited (ASX: DXB) announced that its ACTION3 Phase 3 clinical trial has completed recruitment and dosing of its target 286th adult patient for DMX-200, a treatment for focal segmental glomerulosclerosis (FSGS).

The trial explores the efficacy and safety of DMX-200 in FSGS patients when combined with standard blood pressure medication over two years. Of the 286 adult patients dosed, 69 have completed the full two-year treatment period, with 65 entering the Open Label Extension study, representing 94% uptake.

The study has passed seven scheduled Independent Data Monitoring Committee reviews with no protocol changes required or safety concerns identified. The trial opened

Dimerix completes recruitment for DMX-200 kidney disease trial

Mon, 15 Dec 2025 02:00:20 -0400

The study has passed seven scheduled Independent Data Monitoring Committee reviews with no protocol changes required or safety concerns identified. The trial opened

Dimerix completes recruitment for DMX-200 kidney disease trial

Mon, 15 Dec 2025 02:00:20 -0400

The study has passed seven scheduled Independent Data Monitoring Committee reviews with no protocol changes required or safety concerns identified. The trial opened

Dimerix completes recruitment for DMX-200 kidney disease trial

Mon, 15 Dec 2025 02:00:20 -0400

The study has passed seven scheduled Independent Data Monitoring Committee reviews with no protocol changes required or safety concerns identified. The trial opened

DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT

Mon, 15 Dec 2025 02:00:00 -0400

Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial^[1], which has recruited and dosed its target 286^th adult patient
The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressure medication over 2 years
Of the 286 adult patients dosed in the trial, 69 have already completed the full 2-year treatment period and of those, 65 entered voluntarily into the Open Label Extension (OLE) study, representing 94% OLE uptake
The study has now successfully passed seven scheduled Independent Data Monitoring Committee (IDMC) reviews with no changes to the